Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Racial Differences in Statin Use

JAMA Cardiol; ePub 2018 Jun 13; Nanna, et al

African American outpatient adults were less likely to receive guideline-recommended statin therapy compared to white adults, and this was explained by demographic, clinical, socioeconomic, belief-related, and clinician factors. Researchers analyzed data from the 2015 Patients and Provider Assessment of Lipid Management (PALM) Registry to compared statin use and dosing between African American and white outpatient adults who were potentially eligible for primary or secondary prevention statins. 138 US community health care practices contributed to the data. Primary outcomes were use and dosing of statin therapy according to the 2013 American College of Cardiology/American Heart Association guideline by African American and white race. Among the details:

  • 5,689 patients (806[14.2%] African American) were eligible for statin therapy.
  • African American were less likely that white individuals to be treated with a statin, although this association was no longer significant after adjusting for demographic characteristics, clinical characteristics, socioeconomic status, patient beliefs, and clinician factors.
  • African Americans were less likely that white individuals to believe statins were safe or effective.

Citation:

Nanna MG, Navar AM, Zakroysky P, et al. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use. Insights from the patient and provider assessment of lipid management registry. [Published online ahead of print June 13, 2018]. JAMA Cardiol. doi:10.1001/jamacardio.2018.1511.

This Week's Must Reads

Evolocumab Lowers LDL-C in Patient Subgroups, Clin Cardiol; 2018 Oct 21; Stroes, Robinson, et al

Is Further Lowering of LDL-C in Patients Safe?, JAMA Cardiol; 2018 Sep; Sabatine, Wiviott, et al

Effects of Primary Prevention on CVD Event Risk, J Manag Care Spec Pharm; 2018 Nov; Han, et al

FH Patients with Diabetes at Elevated Risk for CVD, J Clin Lipidol; ePub 2018 Sep 17; Paquette, et al

Long-Term Benefit to Statin Eligibility, JAMA Cardiol; ePub 2018 Oct 24; Thanassoulis, et al

Must Reads in Hypercholesterolemia

Evolocumab Lowers LDL-C in Patient Subgroups, Clin Cardiol; 2018 Oct 21; Stroes, Robinson, et al

Is Further Lowering of LDL-C in Patients Safe?, JAMA Cardiol; 2018 Sep; Sabatine, Wiviott, et al

Effects of Primary Prevention on CVD Event Risk, J Manag Care Spec Pharm; 2018 Nov; Han, et al

FH Patients with Diabetes at Elevated Risk for CVD, J Clin Lipidol; ePub 2018 Sep 17; Paquette, et al

Long-Term Benefit to Statin Eligibility, JAMA Cardiol; ePub 2018 Oct 24; Thanassoulis, et al